Health & Medicine

STAT+: Biogen to acquire immunology biotech Apellis for $5.6 billion

28 sec read14 views0 listens

Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, significantly enhancing its immunology drug portfolio with Syfovre and another commercial asset. This move offers developers and tech professionals in biotech a notable example of how large pharmaceutical companies are expanding through strategic acquisitions to integrate advanced treatments into their offerings. Watch for potential shifts in Biogen’s research focus towards more immunological disorders following this acquisition.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Henry Schein hits ecommerce platform goal in Q1

Henry Schein achieved its goal of consolidating over 80% of U.S. dental e-commerce sales through its new HenrySchein.com platform in Q1, marking a significant milestone for the company's BOLD+1 strategic plan aimed at high-growth areas. This developm...

Ali Nemati

AI & Machine LearningMay 523 sec read

After Paddle Rejected My SaaS, I Realized Payments Care More About Flows Than Features

Payment processors prioritize understanding business flows over detailed features to assess risk and operational supportability. This means explaining clear money paths, including payment models, customer interactions, and dispute handling, is crucia...

Ali Nemati

AI & Machine LearningApr 1326 sec read

Building a PCI-DSS Compliant DevSecOps CI/CD Pipeline for a Fintech Using .NET

A fintech company has implemented a PCI-DSS compliant CI/CD pipeline for .NET that includes rigorous security checks before code reaches production, ensuring compliance and reducing vulnerabilities. This comprehensive approach, involving dynamic, sta...

Ali Nemati

Biotech & PharmaMar 527 sec read

STAT+: Eli Lilly launches program for employers to subsidize cost of obesity drug outside insurance

Eli Lilly has launched a program enabling employers to subsidize the cost of its obesity drug Zepbound outside traditional insurance, offering it at $449 per month. This move aims to address employer hesitance over high medication costs by providing ...

Ali Nemati

Health & MedicineFeb 2726 sec read

He Needs an Expensive Drug. A Copay Card Helped - Until It Didn't.

Jayant Mishra received a copay card to help afford his expensive Otezla medication for psoriatic arthritis but faced unexpected high costs when the card's funds ran out. This highlights the unpredictable nature of copay assistance programs and the ch...

Ali Nemati

STAT+: Biogen to acquire immunology biotech Apellis for $5.6 billion

Related Articles

Henry Schein hits ecommerce platform goal in Q1

After Paddle Rejected My SaaS, I Realized Payments Care More About Flows Than Features

Building a PCI-DSS Compliant DevSecOps CI/CD Pipeline for a Fintech Using .NET

STAT+: Eli Lilly launches program for employers to subsidize cost of obesity drug outside insurance

He Needs an Expensive Drug. A Copay Card Helped - Until It Didn't.